Related Experiment Videos
[Bone marrow transplantation in severe aplastic anemia].
Deutsche Medizinische Wochenschrift (1946)
|April 11, 1986
Summary
Bone marrow transplantation is the preferred treatment for severe aplastic anemia in patients under 40 with matched sibling donors. This life-saving procedure offers a high survival rate and complete recovery.
Area of Science:
- Hematology
- Transplantation Immunology
- Internal Medicine
Background:
- Severe aplastic anemia (SAA) is a life-threatening condition characterized by bone marrow failure.
- Hematopoietic stem cell transplantation (HSCT) is a potential cure for SAA, but early rejection remains a challenge.
Purpose of the Study:
- To evaluate the efficacy and safety of bone marrow transplantation (BMT) in patients with severe aplastic anemia.
- To identify optimal treatment strategies for different age groups with SAA.
Main Methods:
- Retrospective analysis of 15 patients (aged 5-39 years) with SAA who underwent BMT.
- Prophylactic measures against graft rejection included total-body irradiation, cyclosporine A, and buffy-coat transfusion.
Main Results:
- Twelve out of 15 patients achieved complete hematopoietic recovery and survived for a median of 668 days post-transplant.
- Early graft rejection was effectively prevented by the prophylactic measures.
- Treatment-related mortality occurred in three patients due to pneumonia and splenic artery aneurysm bleeding.
Conclusions:
- For patients under 40 with SAA and available HLA-identical sibling donors, early BMT is the treatment of choice.
- For patients over 40, initial treatment with antithymocyte globulin is recommended, reserving BMT for refractory cases.